Informations

Immune thrombocytopenia (ITP) is an autoimmune disorder characterized by antibody-mediated platelet destruction and impaired platelet production, resulting in an increased risk of bleeding. In children, the annual incidence of ITP is approximately 1.9 to 6.4 per 100,000, making it the most common cause of acquired thrombocytopenia in pediatric patients. While most children achieve spontaneous remission…

In recent years, growing understanding of the structural and immune microenvironmental features of hepatocellular carcinoma (HCC) has placed immunotherapy at the forefront of HCC research and treatment. The emergence of immune checkpoint inhibitors (ICIs) and adoptive cell therapy (ACT) has opened new avenues of hope for patients with HCC. ACT, in particular, is a promising…

Hepatocellular carcinoma (HCC) is a major global health burden and a leading cause of cancer-related mortality. Curative hepatectomy is often not feasible due to advanced disease or insufficient liver function. Transarterial chemoembolization (TACE) remains the standard treatment for patients in the intermediate stage, and in some guidelines, even for advanced stages. However, the landscape has…

Editor’s Note At the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, the ANCHOR study, led by Professor Kefeng Ding from the Second Affiliated Hospital of Zhejiang University School of Medicine, was presented as a Late-Breaking Abstract (LBA), marking a significant breakthrough in the treatment landscape of advanced colorectal cancer.

Editor’s Note At the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, three high-impact studies targeting KRAS G12C-mutant colorectal cancer (CRC) revealed groundbreaking progress in precision oncology. KRAS G12C is a notoriously difficult-to-treat molecular subtype of CRC, historically plagued by limited therapeutic options. However, the presentation of data from the CodeBreaK 101 study, a…

Now, results from the global, randomized, open-label, Phase III ROSELLA trial have drawn significant attention. The study evaluated relacorilant, a selective glucocorticoid receptor (GR) antagonist, in combination with nab-paclitaxel in…

This Phase III clinical trial is the first to explore a “dual maintenance” strategy using the domestic PD-L1 inhibitor bemosotamab in combination with the anti-angiogenic agent anlotinib. The results showed…

This study focused on the efficacy and safety of the combination therapy KN046 and KN026 in patients with HER2-positive breast cancer who had failed second-line or later treatments. Using single-cell…